Not checked for notices yet.
KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
Melyssa S. Roberts, Lindsey J. Anstine, Viviane S. Finke and 6 more
Breast Cancer Research · 2020
doi:10.1186/s13058-020-01305-7
Cited by papers we hold 2
- KLF4 transcription factor in tumorigenesis · 2023No notice
- Exosomal targeting and its potential clinical application · 2022No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.